

Company name— Mana.bio---- * Website- <https://www.mana.bio/> ---- * CEO name---
Yogev Debbi----*

CATEGORY: Biotech/Pharma SESSIONS

o Has AI revolutionized drug discovery and clinical development? o Next Generation of Genetic Medicine o Executive Summary / Investment Rational: Mana.bio is an AI-based drug delivery startup focusing on ex-liver oligonucleotide delivery. The RNA/CRISPR market's main bottleneck is ex-liver delivery, and AI has the potential to unlock it. Mana.bio's AI models achieved novel IP-protected in vivo results, including lung-specific delivery. Mana.bio, led by serial entrepreneurs and leading drug delivery and AI professors, was incorporated in October 2021 and raised \$19.5M.

o Core Technology The technology is powered by the integration of machine learning and nanotechnology to predict formulations of lipid nanoparticle drug delivery systems. The company utilizes public data and generates high-throughput data in-house to build an AI engine that can identify lipids and LNP compositions to use as drug delivery vehicles for given payloads such as mRNA and CRISPR gRNA.

o Product Profile/Pipeline Mana.bio leverages, for the first time, a novel approach of AI-driven nanoparticle design that enables molecule prediction and formulation optimization and unlocks delivery to tissues outside the liver, enabling new therapies that open an enormous market opportunity. After achieving novel IPprotected lung RNA delivery, Mana is exploring potential partnerships to leverage it alongside collaborations for other tissue delivery.

o Business Strategy Mana.bio has an AI engine that predicts lipids and LNP compositions as drug delivery vehicles for given payloads such as mRNA and CRISPR gRNA. As our focus is delivery, we look for collaboration with partners who are experts in payload and target discovery. The collaboration will either be licensing out our delivery solutions or in-license payload for the internal pipeline.

o What's Next? Mana.bio plans to continue improving its AI platform further to validate its existing delivery assets, such as lung delivery, and to unlock more non-liver organ delivery that does not yet have a delivery solution in the market. In addition, Mana plans to engage with partners to leverage its programmable delivery platform and achieve collaborations to advance new drugs to clinic.